Where does Probiodrug AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Probiodrug AG ranks #15,551 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Probiodrug AG hold?

Probiodrug AG holds 19 US utility patents granted between 2015 and 2021, spanning 8 technology areas.

What is Probiodrug AG's Innovation Score?

Probiodrug AG has an Innovation Score of 32.7 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Probiodrug AG focus on?

Probiodrug AG's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Probiodrug AG's patent grant rate increasing or decreasing?

Probiodrug AG's recent grant velocity is -88% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Probiodrug AG's patents?

Probiodrug AG's patents average 20.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Probiodrug AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Probiodrug AG

USPTO PatentsView assignee record - 19 granted patents across 8 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Probiodrug ranks #15,551 of 49,997 tracked US assignees by granted-patent volume, with 19 patents across 8 technology areas.

#15,551
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.7/100): 20.5
avg claims per patent: -88%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15551 · Foreign Corporation #15,551 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 19 grants
MID-PACK #15,551/49,997
PHOTO-FINISH Paradigm Sciences
CPC-NARROW A61P · 8 areas
INNOV-THIN 32.7/100
CLAIMS-DENSE 20.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -88% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Paradigm Sciences Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Probiodrug’s 32.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.3 pts (32%) Velocity 0.0 pts (0%) Breadth 10.0 pts (31%) Claim depth 12.3 pts (38%)

Qualcomm Incorporated · highest

85
Probiodrug · this assignee

33
3D Lighting… · lowest

7

What this shows Probiodrug's Innovation Score is 32.7/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Probiodrug?

Each dot is one of Probiodrug’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Probiodrug’s own 20.5 claims/patent is ABOVE the 15.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Probiodrug vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Probiodrug's grants concentrate

Probiodrug AG is a focused PatentsView assignee: 8 CPC subclasses with 84.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (8 grants) versus a trough of 1 in 2020. By volume, Probiodrug sits between PQSecure Technologies, LLC and Paradigm Sciences Ltd..

Pqsecure

19
Preco

19
Preferred Technol…

19
Premark FEG L L C

19
Prodrone

19
Progenity

19
Prose

19
Paradigm Sciences

19
Probiodrug ◀

19

What this shows Probiodrug holds 19 patents at rank #15,533, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Probiodrug

By rank, the assignees closest to #15,533 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Probiodrug's primary technology class.

Probiodrug's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Probiodrug AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	42.1%
2016	4	21.1%
2017	5	26.3%
2020	1	5.3%
2021	1	5.3%

Which technologies does Probiodrug AG patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 11

C07D - Heterocyclic Compounds 9

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C07K - Peptides 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Probiodrug AG's patent record in context - here's where to go next.

Probiodrug AG's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #15,551 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Probiodrug AG against PQSecure Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.